Abstract | BACKGROUND: METHODS: LSL-KrasG12D/+; Pdx1-Cre (KC) mouse model was established to investigate the effect of metformin in pancreatic tumorigenesis suppression; LSL-KrasG12D/+; Trp53fl/+; Pdx1-Cre (KPC) mouse model was used to evaluate the therapeutic efficiency of metformin in PDAC. Chronic pancreatitis was induced in KC mice by peritoneal injection of cerulein. RESULTS: Following metformin treatment, pancreatic acinar-to-ductal metaplasia (ADM) and mouse pancreatic intraepithelial neoplasia (mPanIN) were decreased in KC mice. Chronic pancreatitis induced a stroma-rich and duct-like structure and increased the formation of ADM and mPanIN lesions, in line with an increased cytokeratin 19 (CK19)-stained area. Metformin treatment diminished chronic pancreatitis-mediated ADM and mPanIN formation. In addition, it alleviated the percent area of Masson's trichrome staining, and decreased the number of Ki67-positive cells. In KPC mice, metformin inhibited tumor growth and the incidence of abdominal invasion. More importantly, it prolonged the overall survival. CONCLUSIONS:
|
Authors | Ke Chen, Weikun Qian, Zhengdong Jiang, Liang Cheng, Jie Li, Liankang Sun, Cancan Zhou, Luping Gao, Meng Lei, Bin Yan, Junyu Cao, Wanxing Duan, Qingyong Ma |
Journal | Molecular cancer
(Mol Cancer)
Vol. 16
Issue 1
Pg. 131
(07 24 2017)
ISSN: 1476-4598 [Electronic] England |
PMID | 28738823
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Keratin-19
- Ki-67 Antigen
- Metformin
|
Topics |
- Animals
- Carcinogenesis
(drug effects, metabolism)
- Carcinoma in Situ
(drug therapy, metabolism)
- Carcinoma, Pancreatic Ductal
(drug therapy, metabolism)
- Disease Models, Animal
- Disease Progression
- Keratin-19
(metabolism)
- Ki-67 Antigen
(metabolism)
- Metformin
(pharmacology)
- Mice
- Mice, Transgenic
- Pancreas
(drug effects)
- Pancreatic Ducts
(drug effects, metabolism)
- Pancreatic Neoplasms
(drug therapy, metabolism)
- Pancreatitis, Chronic
(drug therapy, metabolism)
|